Dr. Abou-Alfa Discusses Results of the CELESTIAL Trial in Advanced HCC

Ghassan K. Abou-Alfa, MD
Published: Saturday, Jan 20, 2018



Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the results of the CELESTIAL trial in advanced hepatocellular carcinoma (HCC) during the 2018 Gastrointestinal Cancers Symposium.

The CELESTIAL trial compared cabozantinib (Cabometyx) versus placebo in patients with advanced HCC who have received prior sorafenib (Nexavar). Results from this randomized phase III trial showed a median overall survival (OS) of 10.2 months for the cabozantinib arm versus 8 months for the placebo arm (HR 0.76, 95% CI, 0.63-0.92; P = .0049)—which is clinically and statistically significant, says Abou-Alfa. Additionally, the median progression-free survival was 5.3 months for cabozantinib compared with 1.9 months with placebo (HR, 0.44; 95% CI, 0.36-0.52; P <.001).

These results indicate that cabozantinib showed an improvement in OS when administered after treatment with sorafenib. Abou-Alfa says that these findings provide a durable and well-tolerated second-line option for patients with advanced HCC.
 


Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the results of the CELESTIAL trial in advanced hepatocellular carcinoma (HCC) during the 2018 Gastrointestinal Cancers Symposium.

The CELESTIAL trial compared cabozantinib (Cabometyx) versus placebo in patients with advanced HCC who have received prior sorafenib (Nexavar). Results from this randomized phase III trial showed a median overall survival (OS) of 10.2 months for the cabozantinib arm versus 8 months for the placebo arm (HR 0.76, 95% CI, 0.63-0.92; P = .0049)—which is clinically and statistically significant, says Abou-Alfa. Additionally, the median progression-free survival was 5.3 months for cabozantinib compared with 1.9 months with placebo (HR, 0.44; 95% CI, 0.36-0.52; P <.001).

These results indicate that cabozantinib showed an improvement in OS when administered after treatment with sorafenib. Abou-Alfa says that these findings provide a durable and well-tolerated second-line option for patients with advanced HCC.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Medical Crossfire®: Bridging Emerging Data to Advance Treatment Planning for Hepatocellular Carcinoma: A Multidisciplinary Tumor BoardMar 31, 20182.0
Publication Bottom Border
Border Publication
x